0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TNFSF11

TNFSF11

Brief Information

Name:Tumor necrosis factor ligand superfamily member 11
Target Synonym:Osteoclast differentiation factor,TRANCE,TNFSF11,TNF-related activation-induced cytokine,Tumor necrosis factor ligand superfamily member 11,CD254,TNF Superfamily Member 11,Osteoprotegerin Ligand,Receptor Activator Of Nuclear Factor Kappa B Ligand,Tumor Ne
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:18
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

RAL-H5265-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Human RANK, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. RAK-H5251) on CM5 chip via Anti-Mouse antibodies surface can bind Human TNFSF11, Fc Tag (Cat. No. RAL-H5265) with an affinity constant of 0.574 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

RAL-H5240-SPR
Human_FcRn_Heterodimer_Protein_SPR

Anti-TNFSF11 (human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TNFSF11, His Tag (active trimer) (Cat. No. RAL-H5240) with an affinity constant of 0.274 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

RANKL,CD254,TRANCE,OPGL,ODF

Background

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Denosumab AMG-162; NSC-744010 Approved Amgen Inc Xgeva, Pralia, Prolia, Ranmark Mainland China Osteoporosis, Postmenopausal Amgen Inc 2010-05-26 Bone Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Breast Neoplasms; Prostatic Neoplasms; Osteogenesis Imperfecta; Giant Cell Tumors; Colorectal Neoplasms; Giant Cell Tumor of Bone; Kidney Diseases; Fractures, Bone; Thyroid Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Solid tumours; Hodgkin Disease; Colonic Neoplasms; Hypercalcemia; Osteoporosis, Postmenopausal; Arthritis, Rheumatoid; Carcinoma; Parathyroid Neoplasms; Osteoporosis; Bone Diseases, Metabolic; Hematologic Neoplasms; Endocrine Gland Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Cataract; Bone metastases Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Denosumab biosimilar (AryoGen) Phase 3 Clinical Aryogen Biopharma Osteoporosis; Osteoporosis, Postmenopausal Details
Denosumab biosimilar (Sandoz) GP-2411 Phase 3 Clinical Novartis Pharma Ag, Sandoz Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL antibody(Shanghai Henlius Biotech) HLX14 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL antibody (Innovent Biologics) IBI-307 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Osteoporosis Details
Denosumab biosimilar (Intas Biopharmaceuticals) Phase 3 Clinical Intas Biopharmaceuticals Osteoporosis, Postmenopausal Details
Denosumab biosimilar (Samsung Bioepis) SB-16 Phase 3 Clinical Samsung Bioepis Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL antibody (Alphamab) KN-012 Phase 3 Clinical Suzhou Alphamab Co Ltd Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL antibody (Hisun Pharma) HS629 Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Solid tumours; Bone metastases Details
GB-223 GB-223 Phase 1 Clinical Genor Biopharma Co Ltd Solid tumours; Bone metastases; Osteoporosis, Postmenopausal; Hypercalcemia; Bone Neoplasms; Giant Cell Tumor of Bone Details
Denosumab biosimilar (Qilu Pharma) QL-1206 Phase 3 Clinical Qilu Pharmaceutical Co Ltd Bone metastases; Solid tumours; Osteoporosis, Postmenopausal Details
LZM-004 LZM-004 Phase 1 Clinical Livzon(Group) Pharmaceutical Factory Bone metastases Details
Recombinant human anti-RANKL momoclonal antibody (Hualan Biological Engineering) Phase 1 Clinical Hualan Genetic Engineering Co Ltd Solid tumours; Osteoporosis, Postmenopausal Details
Denosumab biosimiliar (Celltrion) CT-P41 Phase 3 Clinical Celltrion Osteoporosis, Postmenopausal Details
Denosumab biosimilar (Boan Biopharma/Luye Pharma) LY-06006; LY-01011 Phase 3 Clinical Shandong Boan Biotechnology Co Ltd, Luye Pharma Group Ltd Bone metastases; Osteoporosis; Osteoporosis, Postmenopausal; Bone Neoplasms; Neoplasm Metastasis Details
HS-20090-2 Phase 1 Clinical Shanghai Hansoh Biomedical Co Ltd Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL antibody (Jiangsu T-mab BioPharma) MW031; MW032; TK-006 Phase 3 Clinical Jiangsu T-Mab Bio-Pharmaceuticals Co Ltd Bone metastases; Solid tumours; Osteoporosis; Osteoporosis, Postmenopausal; Breast Neoplasms; Bone Neoplasms Details
Recombinant aiti-RANKL human monoclonal antibody (Shanghai Hansoh) Phase 1 Clinical Shanghai Hansoh Biomedical Co Ltd Osteoporosis, Postmenopausal; Neoplasms Details
JMT103 JMT-103 Phase 3 Clinical Shanghai Jinmante Biological Technology Co Ltd Bone metastases; Solid tumours; Osteoporosis; Hypercalcemia; Giant Cell Tumor of Bone Details
Denosumab biosimilar(Fresenius Kabi) FKS-518 Phase 3 Clinical Fresenius Kabi Swissbiosim Gmbh Osteoporosis, Postmenopausal Details
Recombinant human anti-RANKL momoclonal antibody (Qilu Pharmaceutical) Phase 3 Clinical Qilu Pharmaceutical Co Ltd Osteoporosis, Postmenopausal; Neoplasms Details
AP-002 LX-001; AP-002 Phase 2 Clinical Altum Pharmaceuticals Solid tumours Details

This web search service is supported by Google Inc.

totop